KBI Biopharma and Argonaut form drug manufacturing alliance
17 Jan 2024
Preview
Source: Pharmaceutical Technology
The new alliance will offer end-to-end drug manufacturing solutions for biopharmaceutical companies. Credit: IM Imagery / Shutterstock.com.
Contract development and manufacturing organisations (CDMOs) KBI Biopharma and Argonaut Manufacturing Services have formed a strategic partnership to provide biopharmaceutical clients with comprehensive solutions from drug substance to drug product manufacturing.
The collaboration is set to streamline development and cGMP [current good manufacturing practice] processes for their clients.
The collaboration aims to support clients in delivering clinical and commercial therapies to patients rapidly and safely.
Argonaut founder and CEO Wayne Woodard stated: “We believe this strategic alliance resolves a key issue for biopharmaceutical organisations as it greatly improves the alignment and integration between two complex and critical aspects of drug development and manufacturing.
“Biopharmaceutical companies will benefit from an integrated solution that is faster, more flexible and leverages the unique expertise of our two organisations.
“Argonaut’s fill-finish capabilities are scalable from first-in-human clinical material for rare diseases through commercial batches of approved products.”
Argonaut secured a capital investment in January 2023 to significantly expand the capacity of its manufacturing sites in Carlsbad, California, US.
KBI Biopharma president and CEO JD Mowery stated: “At KBI Biopharma, we have always been committed to delivering innovative solutions that accelerate the development and manufacturing of life-saving therapeutics.
“Our state-of-the-art facilities and world-class team have consistently pushed the boundaries of what is possible in biopharmaceutical development.”
Partners across the world are leveraging the technologies of KBI to progress more than 170 drug candidates in preclinical and clinical development and the production of ten commercial assets.
In September 2023, KBI unveiled its SUREmAb offering. This permits streamlined and cost-effective development and production of monoclonal antibodies.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.